Clinical Trials
13 trialsNCT06052306 2026-06-15
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Bayer
Phase 1 Active not recruiting
NCT06909825 2026-06-09
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Fusion Pharmaceuticals Inc.
Phase 2 Active not recruiting
NCT05613894 2026-06-08
CaboLu
University of Utah
Phase 1 Suspended
NCT03732820 2026-06-02
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT06031805 2026-06-02
PROWESs
AstraZeneca
Recruiting
NCT06228053 2026-06-02
SYNERGY-201
Syntrix Biosystems, Inc.
Phase 2 Recruiting
NCT04109729 2026-06-01
Rad2Nivo
University of Utah
Phase 1 Active not recruiting
NCT06514521 2026-06-01
Post Marketing Study on Pluvicto in Korea
Novartis
Recruiting
NCT07608718 2026-05-27
Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07609225 2026-05-27
Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy
University of Wisconsin, Madison
Phase EARLY_PHASE1 Not yet recruiting
NCT06492122 2026-05-26
ProTACT
Full-Life Technologies GmbH
Phase 1 Recruiting
NCT05682443 2026-05-22
PRESERVE-006
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT06533644 2026-05-18
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Syncromune, Inc.
Phase 2 Recruiting